A R T I C L E S
Torikai et al.
identified;17 the toxins share a common binding site on an R
subunit of voltage-sensitive sodium channels (VSSCs), with very
high affinity as shown by their dissociation constants in the
nanomolar-subnanomolar range. Because of the structural
similarity, molecular targets of LSPs are considered to be
transmembrane (TM) proteins including ion channels or recep-
tors. For mode-of-action studies of LSPs, most of which are
hardly obtainable from natural sources, total synthesis of the
LSPs, in which remarkable progress has been made in the recent
decade,18 should be crucial. As a matter of fact, by using
synthetic specimens,19,20 it has been revealed that gambierol
selectively inhibits the voltage-gated K+ channels in mouse taste
cells, while CTX3C is ineffective against the same channels,
although markedly affecting the ion currents through voltage-
gated Na+ channels.21 Furthermore, gambierol has recently been
shown to be a TRPV1 (transient receptor potential vanilloid 1)
antagonist.22
It is reported that the binding of PbTx-3 (a brevetoxin-B
derivative) to VSSCs was competitively inhibited by the addition
of not only ciguatoxin (Ki ) 0.15 nM) but also gambieric acid-A
(Ki ) 0.11 µM) and gambierol (Ki ) 1.4 µM) while their
affinities are 104∼106 times lower than that of ciguatoxin.23
Although it is suggested that there is a significant relationship
between the size of the polycyclic region and the inhibitory
activity,23,24 yessotoxin did not inhibit the binding despite the
same number of rings as brevetoxin-B (undecacyclic).23 In
addition, it is reported that the Ki value of a small pentacyclic
LSP, brevenal,5 is 1.85 µM, which is comparable to that of
gambierol (heptacyclic). Therefore, not only the size of the
polycyclic region (number of rings), but also molecular shape
and functional groups of the LSP should be taken into
consideration upon estimating the affinity of LSPs to VSSCs.
The structural diversity of natural LSPs, differing in length
(including the number of rings and side chains), shape (the order
of connected ring sizes), and functional groups, has been an
obstacle for quantitative structure-activity relationship (SAR)
studies. To sort out the size effects of the polycyclic region
from other factors on the biological activities, it is necessary to
prepare model compounds as molecular probes that are com-
posed of a consistent ring sequence with different length, which
are unavailable from natural sources. Recently, syntheses of
model compounds mimicking LSPs have been reported by
Martin,25 Oguri,26 Tachibana,27 and our groups,28,29 for the
purpose of elucidating the molecular basis for biological
(4) Prasad, A. V. K.; Shimizu, Y. J. Am. Chem. Soc. 1989, 111, 6476–
6477.
(5) Bourdelais, A. J.; Jacocks, H. M.; Wright, J. L. C.; Bigwarfe, P. M.,
Jr.; Baden, D. G. J. Nat. Prod. 2005, 68, 2–6.
(6) (a) Murata, M.; Legrand, A.-M.; Ishibashi, Y.; Yasumoto, T. J. Am.
Chem. Soc. 1989, 111, 8929–8931. (b) Murata, M.; Legrand, A.-M.;
Ishibashi, Y.; Fukui, M.; Yasumoto, T. J. Am. Chem. Soc. 1990, 112,
4380–4386. (c) Satake, M.; Morohashi, A.; Oguri, H.; Oishi, T.;
Hirama, M.; Harada, N.; Yamamoto, T. J. Am. Chem. Soc. 1997, 119,
11325–11326. (d) Yasumoto, T.; Igarashi, T.; Legrand, A.-M.; Cruchet,
P.; Chinain, M.; Fujita, T.; Naoki, H. J. Am. Chem. Soc. 2000, 122,
4988–4989. (e) Lewis, R. J.; Sellin, M.; Poli, M. A.; Norton, R. S.;
MacLeod, J. K.; Sheil, M. M. Toxicon 1991, 29, 1115–1127.
(7) (a) Satake, M.; Murata, M.; Yasumoto, T. Tetrahedron Lett. 1993,
34, 1975–1978. (b) Satake, M.; Fukui, M.; Legrand, A.-M.; Cruchet,
P.; Yasumoto, T. Tetrahedron Lett. 1998, 39, 1197–1198.
(8) (a) Nagai, H.; Torigoe, K.; Satake, M.; Murata, M.; Yasumoto, T.;
Hirota, H. J. Am. Chem. Soc. 1992, 114, 1102–1103. (b) Nagai, H.;
Murata, M.; Torigoe, K.; Satake, M.; Yasumoto, T. J. Org. Chem.
1992, 57, 5448–5453. (c) Morohashi, A.; Satake, M.; Nagai, H.;
Oshima, Y.; Yasumoto, T. Tetrahedron 2000, 56, 8995–9001.
(9) (a) Satake, M.; Murata, M.; Yasumoto, T. J. Am. Chem. Soc. 1993,
115, 361–362. (b) Morohashi, A.; Satake, M.; Yasumoto, T. Tetra-
hedron Lett. 1999, 40, 97–100.
(19) (a) Total syntheses of gambierol, see: Fuwa, H.; Sasaki, M.; Satake,
M.; Tachibana, K. Org. Lett. 2002, 4, 2981–2984. (b) Fuwa, H.;
Kainuma, N.; Tachibana, K.; Sasaki, M. J. Am. Chem. Soc. 2002, 124,
14983–14992. (c) Kadota, I.; Takamura, H.; Sato, K.; Ohno, A.;
Matsuda, K.; Yamamoto, Y. J. Am. Chem. Soc. 2003, 125, 46–47. (d)
Kadota, I.; Takamura, H.; Sato, K.; Ohno, A.; Matsuda, K.; Satake,
M.; Yamamoto, Y. J. Am. Chem. Soc. 2003, 125, 11893–11899. (e)
Johnson, H. W. B.; Majumder, U.; Rainier, J. D. J. Am. Chem. Soc.
2005, 127, 848–849. (f) Majumder, U.; Cox, J. M.; Johnson, H. W. B.;
Rainier, J. D. Chem.sEur. J. 2006, 12, 1736–1746. (g) Johnson,
H. W. B.; Majumder, U.; Rainier, J. D. Chem.sEur. J. 2006, 12, 1747–
1753.
(10) Satake, M.; Shoji, M.; Oshima, Y.; Naoki, H.; Fujita, T.; Yasumoto,
T. Tetrahedron Lett. 2002, 43, 5829–5832.
(11) Murata, M.; Kumagai, M.; Lee, J. S.; Yasumoto, T. Tetrahedron Lett.
1987, 28, 5869–5872.
(12) (a) C-CTX: Lewis, R. J.; Vernoux, J.-P.; Brereton, I. M. J. Am. Chem.
Soc. 1998, 120, 5914–5920. (b) gymnocin-B: Satake, M.; Tanaka, Y.;
Ishikura, Y.; Oshima, Y.; Naoki, H.; Yasumoto, T. Tetrahedron Lett.
2005, 46, 3537–3540. (c) prymnecin : Igarashi, T.; Satake, M.;
Yasumoto, T. J. Am. Chem. Soc. 1999, 121, 8499–8511. (d) maito-
toxin: Murata, M.; Naoki, H.; Iwashita, T.; Matsunaga, S.; Sasaki,
M.; Yokoyama, A.; Yasumoto, T. J. Am. Chem. Soc. 1993, 115, 2060–
2062.
(20) Total synthesis of CTX3C, see: (a) Hirama, M.; Oishi, T.; Uehara,
H.; Inoue, M.; Maruyama, M.; Oguri, H.; Satake, M. Science 2001,
294, 1904–1907. (b) Inoue, M.; Uehara, H.; Maruyama, M.; Hirama,
M. Org. Lett. 2002, 4, 4551–4554. (c) Inoue, M.; Miyazaki, K.; Uehara,
H.; Maruyama, M.; Hirama, M. Proc. Natl. Acad. Sci. U.S.A. 2004,
101, 12013–12018. (d) Inoue, M.; Hirama, M. Acc. Chem. Res. 2004,
37, 961–968. (e) Hirama, M. Chem. Rec. 2005, 5, 240–250.
(21) (a) Yamaoka, K.; Inoue, M.; Miyahara, H.; Miyazaki, K.; Hirama,
M. Br. J. Pharmacol. 2004, 142, 879–889. (b) Ghiaroni, V.; Sasaki,
M.; Fuwa, H.; Rossini, G. P.; Scalera, G.; Yasumoto, T.; Pietra, P.;
Bigiani, A. Toxicol. Sci. 2005, 85, 657–665. (c) Ghiaroni, V.; Fuwa,
H.; Inoue, M.; Sasaki, M.; Miyazaki, K.; Hirama, M.; Yasumoto, T.;
Rossini, G. P.; Scalera, G.; Bigiani, A. Chem. Senses 2006, 31, 673–
680. (d) Cuypers, E.; Abdel-Mottaleb, Y.; Kopljar, I.; Rainier, J. D.;
Raes, A. L.; Snyders, D. J.; Tytgat, J. Toxicon 2008, 51, 974–983.
(22) Cuypers, E.; Yanagihara, A.; Rainier, J. D.; Tytgat, J. Biochem.
Biophys. Res. Commun. 2007, 361, 214–217.
(13) (a) Baden, D. G. FASEB J. 1989, 3, 1807–1817. (b) Dechraoui, M.-
Y.; Naar, J.; Pauillac, S.; Legrand, A.-M. Toxicon 1999, 37, 125–
143.
(14) (a) Lewis, R. J.; Sellin, M.; Poli, M. A.; Norton, R. S.; MacLeod,
J. K.; Sheil, M. M. Toxicon 1991, 29, 1115–1127. (b) Vernoux, J.-P.;
Lewis, R. J. Toxicon 1997, 35, 889–900.
(15) Nagai, H.; Mikami, Y.; Yazawa, K.; Gonoi, T.; Yasumoto, T. J.
Antibiot. 1993, 46, 520–522.
(16) Korsnes, M. S.; Hetland, D. L.; Espenes, A.; Tranulis, M. A.; Aune,
T. Toxicol. in Vitro 2006, 20, 1077–1087.
(17) (a) Catterall, W. A.; Risk, M. Mol. Pharmacol. 1981, 19, 345–348.
(b) Trainer, V. L.; Baden, D. G.; Catterall, W. A. J. Biol. Chem. 1994,
269, 19904–19909. (c) Dechraoui, M.-Y.; Naar, J.; Pauillac, S.;
Legrand, A.-M. Toxicon 1999, 37, 125–143.
(23) Inoue, M.; Hirama, M.; Satake, M.; Sugiyama, K.; Yasumoto, T.
Toxicon 2003, 41, 469–474.
(24) Gawley, R. E.; Rein, K. S.; Jeglitsch, G.; Adams, D. J.; Theodorakis,
E. A.; Tiebes, J.; Nicolaou, K. C.; Baden, D. G. Chem. Biol. 1995, 2,
533–541.
(18) Reviews on the total synthesis of ladder-shaped polyethers, see: (a)
Fuwa, H.; Sasaki, M. Curr. Opin. Drug DiscoVery DeV. 2007, 10,
784–806. (b) Nakata, T. Chem. ReV. 2005, 105, 4314–4347. (c) Inoue,
M. Chem. ReV. 2005, 105, 4379–4405. (d) Kadota, I.; Yamamoto, Y.
Acc. Chem. Res. 2005, 38, 423–432. (e) Sasaki, M.; Fuwa, H. Synlett
2004, 1851–1874. (f) Inoue, M. Org. Biomol. Chem. 2004, 2, 1811–
1817. (g) Marmsa¨ter, F. P.; West, F. G. Chem.sEur. J. 2002, 8, 4346–
4353. (h) Evans, P. A.; Delouvrie, B. Curr. Opin. Drug DiscoVery
DeV. 2002, 5, 986–999. (i) Mori, Y. Chem.sEur. J. 1997, 3, 849–
852. (j) Alvarez, E.; Candenas, M.-L.; Pe´rez, R.; Ravelo, J. L.; Mart´ın,
J. D. Chem. ReV. 1995, 95, 1953–1980.
(25) Candenas, M. L.; Pinto, F. M.; Cintado, C. G.; Morales, E. Q.; Brouard,
I.; D´ıaz, M. T.; Rico, M.; Rodr´ıguez, E.; Rodr´ıguez, R. M.; Pe´rez, R.;
Pe´rez, R. L.; Mart´ın, J. D. Tetrahedron 2002, 58, 1921–1942.
(26) (a) Oguri, H.; Oomura, A.; Tanabe, S.; Hirama, M. Tetrahedron Lett.
2005, 46, 2179–2183. (b) Oguri, H.; Tanabe, S.; Oomura, A.; Umetsu,
M.; Hirama, M. Tetrahedron Lett. 2006, 47, 5801–5805.
(27) Sasaki, M.; Tachibana, K. Tetrahedron Lett. 2007, 48, 3181–3186.
(28) Torikai, K.; Yari, H.; Mori, M.; Ujihara, S.; Matsumori, N.; Murata,
M.; Oishi, T. Bioorg. Med. Chem. Lett. 2006, 16, 6355–6359.
9
10218 J. AM. CHEM. SOC. VOL. 130, NO. 31, 2008